We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Technique to Insure Stable Supply of Flu Drug

By HospiMedica staff writers
Posted on 31 Mar 2006
A team of Japanese researchers has developed a new technique for producing the anti-flu drug Tamiflu (ostelamivir) that does not rely on natural ingredients, which may help ensure a more stable supply of the drug in the event of a pandemic.

Researchers at the University of Tokyo's Graduate School of Pharmaceutical Sciences (Japan) have found a way to manufacture Tamiflu without using shikimic acid, produced from a spice called star anise. More...
This brownish star-shaped fruit of the illicium verum tree is often used as a spice in Chinese cuisine. The new technique, called asymmetric catalysis, produces Tamiflu from a petrochemical ingredient called 1,4-cyclohexadiene instead, eliminating weather as a risk factor in Tamiflu production. Tamiflu, produced by Roche (Basel, Switzerland), is considered one of the best defenses against avian flu in humans.

If things go well, I hope we may be able to pave the way towards giving supplies to society in around two years, said Professor Masakatsu Shibasaki, a biochemist and leader of the team that developed the process, adding that he would soon submit a paper on his team's findings to the Journal of the American Chemical Society. Tokyo University has applied for an intellectual property patent in Japan and is now in discussions with Roche on a number of issues regarding further research and licensing.

Asymmetric catalysis is a chemical-reaction process invented by Professor Ryoji Noyori, now president of the Riken Institute (Saitama, Japan), a multi-site Japanese research initiative with an annual budget of U.S.$800 million. He was awarded the 2001 Nobel Prize in chemistry for his development of the process.



Related Links:
U. of Tokyo Grad. School of Pharmaceutical Sciences

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.